Safety and Immunogenicity of V116 in Adults With Increased Risk for Pneumococcal Disease (V116-008)
Status:
Not yet recruiting
Trial end date:
2024-02-19
Target enrollment:
Participant gender:
Summary
The primary objectives of this study are to evaluate the safety and tolerability of the
pneumococcal 21 valent conjugate vaccine (V116), and to evaluate the serotype-specific
opsonophagocytic activity (OPA) post-vaccination with V116 and PCV15 (a pneumococcal
conjugate vaccine that includes 15 serotypes) + PPSV23 (comprised of the polysaccharides from
23 of the serotypes causing disease in adults) post-vaccination. within each vaccination
group separately.